Jubilee Brown, MD

Dr Brown discusses the rationale for the RAMP-301 trial of avutometinib plus defactinib in low-grade serous ovarian cancer.

Jubilee Brown, MD, discusses ongoing investigations into treatments that target the RAS/MAPK pathway in patients with ovarian cancer.

Jubilee Brown, MD, professor, director, gynecologic oncology, Levine Cancer Institute, Atrium Health, discusses benefits associated with PARP inhibitor maintenance therapy in the upfront and recurrent settings of ovarian cancer.

Jubilee Brown, MD, discusses the benefits of minimally invasive surgery in ovarian cancer.

Jubilee Brown, MD, discusses the promise of the phase 2/3 ROCSAN trial in recurrent gynecologic carcinosarcomas.

Jubilee Brown, MD, discusses the utility of PARP inhibitors in patients with recurrent platinum-sensitive ovarian cancer.

Jubilee Brown, MD, discusses the clinical implications of the phase 3 PRIMA trial in advanced ovarian cancer.

Jubilee Brown, MD, discusses future directions for surgery in ovarian cancer.

Jubilee Brown, MD, discusses the utility of minimally invasive surgery in ovarian cancer.

Jubilee Brown, MD, discusses germline and somatic testing in ovarian cancer.

Jubilee Brown, MD, professor of gynecologic oncology, Levine Cancer Institute, Carolinas HealthCare System, discusses the importance of genetic testing in patients with ovarian cancer.

Jubilee Brown, MD, professor of gynecologic oncology, Levine Cancer Institute, Carolinas HealthCare System, discusses the adoption of genetic testing into routine clinical practice.

Jubilee Brown, MD, obstetrician-gynecologist, Levine Cancer Institute, Carolinas HealthCare System, discusses genetic counseling for patients with breast and ovarian cancer.